WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳NO PRODUCTS · NO PROTOCOLS · NO VENDORS✳EDUCATIONAL JOURNALISM · NOT MEDICAL ADVICE✳ WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳NO PRODUCTS · NO PROTOCOLS · NO VENDORS✳EDUCATIONAL JOURNALISM · NOT MEDICAL ADVICE✳
The Peptide Current FDA Peptide Tracker
Official sources checked July 25, 2026
PCAC: Recommend inclusionLast checked · July 25, 2026

KPV: committee recommended inclusion. FDA final is still pending.

The advisory committee recommended inclusion for KPV free base / KPV acetate. The two form-specific votes are advisory and non-binding; FDA's final determination remains pending.

What matters now
The committee recommended inclusion; FDA has not made its final determination.
  • Staff · against inclusion
  • Committee · Recommend inclusion
  • Final FDA action · pending
The decision path

Three stages. The first two are complete.

This tracker separates the stages that headlines often collapse together.

FDA staff review
Against inclusion

Published in FDA’s meeting briefing packet.

PCAC recommendation
Recommend inclusion

KPV (free base): Yes 8, No 6, Abstain 1. KPV acetate: Yes 8, No 6, Abstain 1. Advisory and non-binding.

Final FDA determination
Pending

FDA says it will consider committee input and complete its review.

What staff says

FDA staff says the evaluation criteria weigh against placing KPV free base or KPV acetate on the 503A Bulks List.

FDA says neither form is a component of an FDA-approved drug. The briefing identifies inconsistent naming and uncertainty about which substance a reference standard describes as characterization concerns.

Uses on the agenda
  • Wound healing
  • Inflammatory conditions

The agenda names the uses FDA reviewed; it does not establish that KPV is effective for either use.

Keep the categories straight

What this committee recommendation does not change

It does not place a substance on the list. The advisory vote supplies non-binding advice for FDA’s later action.
It is not FDA’s final determination. FDA says the committee’s advice is non-binding and is one part of its review.
It is not drug approval. FDA’s briefing says neither form is a component of an FDA-approved drug.
It is not a product-quality finding. It does not verify the identity, purity, sterility, or safety of anything sold online.
14-vote package · independently verifiedJuly 23, 2026

The committee recommended inclusion for both forms.

The forms were separate questions and received separate tallies. This is advisory committee input, not FDA approval, final list placement, or FDA's final determination.

FDA voting questionsOfficial PDF ↗FDA meeting page and linked broadcastsOfficial page ↗

Primary verification: July 25, 2026. Independent verification: Claude, July 25, 2026. FDA final action remains pending.

Receipts

Open the official record

FDA staff briefing — KPVOfficial PDF ↗ FDA meeting page and agendaOfficial page ↗ FDA briefing introductionOfficial PDF ↗ Read the KPV evidence entryPepCurrent →
Safety boundary: This page explains public regulatory records. It does not recommend using or avoiding a compound, evaluate an individual product, or provide dosing, sourcing, or treatment advice.
If someone may be having a medical problem

Get help first. Report later.

PepCurrent cannot assess symptoms or provide emergency triage.

Call 911 nowIf someone collapses, has a seizure, has trouble breathing, or cannot be awakened.
U.S. Poison ControlCall 1-800-222-1222 or visit Poison.org.
Personal medical questionsContact a licensed clinician who can evaluate the person and their medical history.
Serious product problemAfter appropriate care, patients and clinicians can use FDA MedWatch.

U.S. resources · checked July 16, 2026 · Open the full Help Now page →